Menopause Patches Emerge as Potential Prostate Cancer Therapy
Patches commonly prescribed to alleviate menopause symptoms in women could provide a novel treatment avenue for a specific form of prostate cancer, according to groundbreaking research from University College London. The study, published in the prestigious New England Journal of Medicine, demonstrates that these transdermal patches deliver oestradiol—a form of oestrogen—through the skin, effectively lowering testosterone levels to curb cancer progression.
Comparative Efficacy with Traditional Injections
The comprehensive trial involved 1,360 men with an average age of 72, recruited from cancer centres across the United Kingdom. Participants were randomly assigned to either wear the patches or receive standard injections designed to block testosterone production. Researchers meticulously compared the two delivery methods over an extended period.
Remarkably, the patches proved equally effective as injections at preventing locally advanced prostate cancer from spreading beyond the gland. This finding challenges conventional treatment protocols that have relied heavily on injection-based hormone therapies for decades.
Side Effect Profile and Patient Convenience
While both treatments successfully suppressed testosterone—a hormone crucial for prostate cancer growth—their side effect profiles differed significantly. The patches resulted in fewer adverse effects compared to injections, which can trigger hot flushes, bone density issues, and cardiovascular risk factors such as elevated cholesterol, blood sugar, and blood pressure.
However, the patches were associated with increased breast tissue swelling, presenting a notable trade-off for patients considering this treatment option.
From a practical standpoint, the patches offer substantial convenience advantages. Patients can apply them at home, eliminating the need for multiple hospital or GP visits required for LHRH agonist injections. This self-administration capability could dramatically improve treatment adherence and quality of life for many men.
Expert Perspectives on Treatment Choices
Lead researcher Professor Ruth Langley from the MRC Clinical Trials Unit at UCL emphasised the importance of patient choice: "We believe our findings should enable men with locally advanced prostate cancer to select the hormone therapy that best suits their individual circumstances. For some patients, debilitating hot flushes significantly impact daily living, making the patches a potentially life-enhancing alternative."
Caroline Geraghty, senior specialist nurse manager at Cancer Research UK, welcomed the research: "While over eighty percent of men diagnosed with prostate cancer now survive a decade or longer, we must continue developing kinder treatments. This trial demonstrates that hormone patches control locally advanced prostate cancer as effectively as traditional injections while being gentler and easier to administer."
Simon Grieveson, assistant director of research at Prostate Cancer UK, added: "Hormone therapy remains extremely common and effective for prostate cancer, but significant side effects often accompany injections. These skin patches offer comparable efficacy in delaying cancer progression with reduced hot flushes, though breast swelling occurs more frequently. Their convenience and reduced invasiveness could empower men with greater treatment choices aligned with their lifestyles."
Broader Context of Prostate Cancer Screening
The publication of these results coincides with crucial discussions about prostate cancer screening in the UK. The UK National Screening Committee (UKNSC), which advises the government, recently convened to determine future screening approaches. In a draft recommendation last year, the committee rejected population-wide screening using the prostate-specific antigen (PSA) test, concluding it "is likely to cause more harm than good."
The UKNSC proposed screening only men with BRCA1 and BRCA2 genetic mutations—which substantially increase prostate cancer risk—every two years between ages 45 and 61. Health Secretary Wes Streeting expressed surprise at this limited approach but stressed that final decisions must be "based on science and evidence, not on politics."
Many medical experts argue that PSA testing lacks reliability, as elevated PSA levels don't always indicate cancer, while some cancer patients show normal PSA results. False positives may lead to unnecessary treatments for slow-growing or harmless tumours, exposing men to risks of incontinence and erectile dysfunction. Conversely, other specialists advocate for broader testing, urging the committee to reconsider its position based on evolving evidence.
The UKNSC's definitive decision will be published several weeks following their Thursday meeting, potentially reshaping prostate cancer detection and treatment strategies nationwide.
